Syndax Pharmaceuticals Inc. (1T3)
XDUS 
Summary
1T3 Chart
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.98 per share a year ago.
Syndax Pharma: Two Drug Launches Fuel Transformational Growth
Syndax Pharma delivered robust Q4 2025 results, with sales of $68.7 million (+794.5% YoY), driven by Revuforj and Niktimvo. Revuforj's rapid commercialization and label expansion position SNDX to access a $5 billion+ AML market, with 1L Phase 3 trials as a major catalyst. Niktimvo's strong launch in GVHD and operational leverage support increasing collaboration revenue, with potential market doubling via frontline studies.
Syndax Pharmaceuticals Inc. (1T3) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Syndax Pharmaceuticals Inc. ever had a stock split?
Syndax Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael A. Metzger CEO | XDUS Exchange | US87164F1057 ISIN |
| US Country | 270 Employees | - Last Dividend | - Last Split | 3 Mar 2016 IPO Date |
Overview
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical organization focused on the discovery and development of novel treatments for cancer. Established in 2005, the company is driven by a commitment to provide innovative therapies that address unmet medical needs in the oncology space. With its headquarters in Waltham, Massachusetts, Syndax Pharmaceuticals has positioned itself as a leader in the fight against cancer, leveraging cutting-edge science and research to develop transformative medicines. The firm’s dedication to advancing cancer treatment is evidenced by its robust pipeline of product candidates and partnerships aimed at enhancing the development and commercialization of its potential treatments. Through strategic collaborations and a deep understanding of cancer biology, Syndax is working to bring new hope to patients suffering from this devastating disease.
Products and Services
- Revumenib
Revumenib stands out as Syndax Pharmaceuticals' leading product candidate, configured as a powerful and selective small molecule inhibitor targeting the menin-MLL binding interaction. It is primarily being developed for the treatment of KMT2A rearranged acute leukemias and solid tumors. Revumenib's mechanism of action disrupts critical protein interactions responsible for the growth of certain cancer cells, offering a novel approach to treating these malignancies.
- SNDX-6352/Axatilimab
Another pivotal product in Syndax's lineup is SNDX-6352, also known as axatilimab. This therapeutic is a monoclonal antibody designed to inhibit the colony stimulating factor 1 receptor (CSF-1R). Its primary indications are for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF), two conditions with significant unmet medical needs. By blocking CSF-1R, axatilimab may help modulate the immune response and alleviate the symptoms of these serious diseases.
- Entinostat
Beyond revumenib and axatilimab, Syndax is also advancing Entinostat, another flagship investigational compound. While specific details regarding its mechanism and targeted indications were not provided in the overview, Entinostat represents a crucial part of the company's diversified portfolio in oncology. Syndax has secured a licensing and development agreement with Eddingpharm International Company Limited, aimed at bolstering the commercialization prospects of Entinostat, indicating its potential significance in cancer treatment regimens.
